In the framework of the European Society of Medical Oncology (ESMO) congress, held in Barcelona from September 13th to 17th, MEDSIR, a company that is part of Oncoclínicas & Co, dedicated to promoting independent clinical research in oncology internationally, hosted an informational breakfast with key players in cancer research to discuss the present and future of breast and lung cancer treatments. Continue reading
Johnson & Johnson (NYSE: JNJ) announced today that 11 oral presentations from the Company’s industry-leading solid tumor portfolio and pipeline will be featured at the 2024 World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) 2024 Congress. Twenty-seven studies (23 company-sponsored and four investigator-initiated), including four late-breaking abstracts, will feature new data in lung, bladder, prostate, and colorectal cancers. Continue reading
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Food and Drug Administration (FDA) approval of its in vitro diagnostic (IVD) TruSight™ Oncology (TSO) Comprehensive test and its first two companion diagnostic (CDx) indications. This single test interrogates over 500 genes to profile a patient’s solid tumor, helping to increase the likelihood of identifying an immuno-oncology biomarker or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment. Continue reading